Table 2 Number and proportion of patients with medical history of respiratory and nonrespiratory diseases, at any time before index date and up to 30 days after and number and proportion of users of respiratory and nonrespiratory comedications within 12 months prior to index date among new users of olodaterol and indacaterol, by data source.
PHARMO Overall | PHARMO-GP | Danish population registers | IMS RWE LPD GP panel | IMS RWE LPD pulmonologist panel | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
Olodaterol (N = 1,386) | Indacaterol (N = 1,841) | Olodaterol (N = 372) | Indacaterol (N = 636) | Olodaterol (N = 1,712) | Indacaterol (N = 6,406) | Olodaterol (N = 696) | Indacaterol (N = 1,592) | Olodaterol (N = 364) | Indacaterol (N = 127) | |
Respiratory diseases, n (%) | ||||||||||
COPD | 663 (47.8) | 653 (35.5) | 276 (74.2) | 407 (64.0) | 1,118 (65.3) | 1,840 (28.7) | 374 (53.7) | 847 (53.2) | 283 (77.7) | 89 (70.1) |
Asthma | 166 (12.0) | 202 (11.0) | 107 (28.8) | 166 (26.1) | 261 (15.2) | 542 (8.5) | 218 (31.3) | 457 (28.7) | 100 (27.5) | 26 (20.5) |
Pneumonia | 210 (15.2) | 184 (10.0) | 52 (14.0) | 87 (13.7) | 565 (33.0) | 1,200 (18.7) | 186 (26.7) | 319 (20.0) | 46 (12.6) | 9 (7.1) |
Other respiratory conditions | 191 (13.8) | 186 (10.1) | 43 (11.6) | 60 (9.4) | 445 (26.0) | 649 (10.1) | 60 (8.6) | 123 (7.7) | 102 (28.0) | 19 (15.0) |
Nonrespiratory diseases, n (%) | ||||||||||
Ischemic heart disease | 213 (15.4) | 258 (14.0) | 49 (13.2) | 71 (11.2) | 405 (23.7) | 1,236 (19.3) | 88 (12.6) | 176 (11.1) | 28 (7.7) | 7 (5.5) |
Arrhythmias | 171 (12.3) | 179 (9.7) | 48 (12.9) | 78 (12.3) | 269 (15.7) | 796 (12.4) | 84 (12.1) | 187 (11.7) | 23 (6.3) | 5 (3.9) |
Heart failure | 87 (6.3) | 88 (4.8) | 29 (7.8) | 37 (5.8) | 183 (10.7) | 384 (6.0) | 20 (2.9) | 46 (2.9) | 5 (1.4) | 0 (0.0) |
Hypertension | 261 (18.8) | 291 (15.8) | 96 (25.8) | 157 (24.7) | 560 (32.7) | 1,737 (27.1) | 305 (43.8) | 682 (42.8) | 85 (23.4) | 17 (13.4) |
Other forms of heart diseases | 179 (12.9) | 226 (12.3) | 68 (18.3) | 110 (17.3) | 384 (22.4) | 1,255 (19.6) | 224 (32.2) | 440 (27.6) | 21 (5.8) | 3 (2.4) |
Cerebrovascular disease | 73 (5.3) | 113 (6.1) | 25 (6.7) | 41 (6.4) | 226 (13.2) | 727 (11.3) | 45 (6.5) | 94 (5.9) | 12 (3.3) | 1 (0.8) |
Hyperlipidemia | 95 (6.9) | 124 (6.7) | 47 (12.6) | 77 (12.1) | 235 (13.7) | 135 (7.9) | 193 (27.7) | 455 (28.6) | 29 (8.0) | 8 (6.3) |
Renal disease | 166 (12.0) | 187 (10.2) | 42 (11.3) | 74 (11.6) | 385 (22.5) | 193 (11.3) | 135 (19.4) | 296 (18.6) | 9 (2.5) | 2 (1.6) |
Depressive disorders | 27 (1.9) | 25 (1.4) | 23 (6.2) | 23 (3.6) | 771 (12.0) | 303 (17.7) | 185 (26.6) | 427 (26.8) | 26 (7.1) | 4 (3.1) |
Diabetes mellitus | 140 (10.1) | 167 (9.1) | 42 (11.3) | 78 (12.3) | 1,061 (16.6) | 543 (8.5) | 109 (15.7) | 236 (14.8) | 35 (9.6) | 10 (7.9) |
Malignancy | 179 (12.9) | 194 (10.5) | 49 (13.2) | 77 (12.1) | 771 (12.0) | 1,047 (16.3) | 85 (12.2) | 179 (11.2) | 44 (12.1) | 6 (4.7) |
Respiratory medications, n (%) | ||||||||||
LABAa | 382 (27.6) | 185 (10.0) | 104 (28.0) | 61 (9.6) | 437 (25.5) | 351 (5.5) | 97 (13.9) | 64 (4.0) | 51 (14.0) | 5 (3.9) |
LABA/ICS | 514 (37.1) | 519 (28.2) | 137 (36.8) | 170 (26.7) | 687 (40.1) | 1,177 (18.4) | 197 (28.3) | 334 (21.0) | 68 (18.7) | 24 (18.9) |
LABA/LAMA | 81 (5.8) | 5 (0.3) | 21 (5.6) | 2 (0.3) | 190 (11.1) | 58 (0.9) | 59 (8.5) | 2 (0.1) | 46 (12.6) | 1 (0.8) |
LAMA | 1,088 (78.5) | 1,081 (58.7) | 275 (73.9) | 368 (57.9) | 1,228 (71.7) | 1,536 (24.0) | 296 (42.5) | 282 (17.7) | 235 (64.6) | 39 (30.7) |
SAMA | 174 (12.6) | 193 (10.5) | 32 (8.6) | 70 (11.0) | 12 (0.7) | 19 (0.3) | 18 (2.6) | 13 (0.8) | 72 (19.8) | 3 (2.4) |
SABA | 623 (44.9) | 643 (34.9) | 140 (37.6) | 210 (33.0) | 991 (57.9) | 2,482 (38.7) | 176 (25.3) | 349 (21.9) | 119 (32.7) | 19 (15.0) |
SABA/SAMA | 105 (7.6) | 54 (2.9) | 25 (6.7) | 9 (1.4) | 98 (5.7) | 95 (1.5) | 23 (3.3) | 38 (2.4) | 20 (5.5) | 15 (11.8) |
ICS | 378 (27.3) | 334 (18.1) | 77 (20.7) | 95 (14.9) | 302 (17.6) | 667 (10.4) | 117 (16.8) | 206 (12.9) | 54 (14.8) | 18 (14.2) |
Systemic glucocorticosteroids | 685 (49.4) | 617 (33.5) | 149 (40.1) | 223 (35.1) | 662 (38.7) | 1,188 (18.5) | 287 (41.2) | 515 (32.3) | 54 (14.8) | 13 (10.2) |
Nonrespiratory medications, n (%) | ||||||||||
Cardiovascular medications | 900 (64.9) | 1,174 (63.8) | 246 (66.1) | 396 (62.3) | 1,245 (72.7) | 4,288 (66.9) | 414 (59.5) | 865 (54.3) | 11 (3.0) | 2 (1.6) |
Systemic antibacterials | 824 (59.5) | 928 (50.4) | 197 (53.0) | 317 (49.8) | 1,179 (68.9) | 3,493 (54.5) | 467 (67.1) | 919 (57.7) | 84 (23.1) | 18 (14.2) |
Proton pump inhibitors | 765 (55.2) | 927 (50.4) | 195 (52.4) | 337 (53.0) | 610 (35.6) | 1,859 (29.0) | 329 (47.3) | 676 (42.5) | 21 (5.8) | 5 (3.9) |
Antithrombotic agents | 602 (43.4) | 761 (41.3) | 145 (39.0) | 261 (41.0) | 710 (41.5) | 2,225 (34.7) | 195 (28.0) | 362 (22.7) | 2 (0.5) | 0 (0.0) |
Drugs for musculoskeletal system | — | — | — | — | 433 (25.3) | 1,511 (23.6) | 219 (31.5) | 428 (26.9) | 1 (0.3) | 0 (0.0) |
